[Clinical Study of XXXX Treated with Enhanced Chemotherapy Regimen and Increased Treatment Courses].

@entity1 @entity66 @entity3726 @entity74 @entity1893
OBJECTIVE: To study the @entity1893 treated with enhanced chemotherapy regimen and increase of treatment courses, including number of treatment courses, short-term efficacy, long-term survival and safety. METHODS: All the 254 cases of @entity1893 in our hospital from January 2004 to February 2014 received a variety of intensive enhanced chemotherapy regimen, such as CHOPE, MAED, MMED and TAED. The median number of treatment course was 14, including 8 in the 1st year, 4 in the 2nd and 2 in the 3rd. RESULTS: (1) In 254 assessable @entity1 , 182 @entity1 (71.7%) achieved complete responses (CR), 30 @entity1 (11.8%) achieved partial responses (PR), 22 @entity1 (8.7%) achieved @entity66 ( @entity66 ), 20 @entity1 (7.9%) achieved @entity74 ( @entity74 ), 212 @entity1 (83.5%) achieved response rate (RR). The median time of following-up was 56.5 months, the overall survivals (OS) of 1, 3 and 5 years were 90.1%, 74.5% and 61.1% respectively, the median survival time was 69 months, and the disease-free survivals (DFS) were 81.8%, 65.4% and 54.7% respectively, the median DFS was 65 months. (2) In therapeutic effects at early phase, the 3-year OS of @entity1 who achieved CR, PR, @entity66 and @entity74 were 92.2%, 56.0%, 20.2% and 0% respectively; The 5-year OS of @entity1 who achieved CR through  <=4 cycle treatments and the 5-year OS of @entity1 who achieved CR through >4 cycles treatments were 83.1% and 6.8%, their DFS were 72.4% and 0% respectively. (3) The relapse rates of @entity1 who received < 6, 6-8, 9-10, 11-13, 14, 15 and 20 cycle treatments were 82.5%, 78.9%, 71.9%, 65.8%, 41.8%, 30.4% and 16.7%. The response rate (RR) of @entity1 who received 6-8 traditional chemotherapy cycle as @entity3726 or @entity3726 -like regimen were 50%-60% and relapse rate > 70%. CONCLUSION: Compared with traditional chemotherapy regimens, the dose-escalated, intensive and modified chemotherapy regimen can significatly improve the therapeutic efficiency for @entity1 with @entity1893 , including CR, long-term survival rate, and a good tolerance for @entity1 . The chemotherapy intensity has been confirmed to be an important factor that associated with therapeutic efficiency. On the conditions tolerated by @entity1 , the number of treatment cycles for @entity1893 @entity1 can be increased at lest 14, with 8 in the first year, 4 in the second year and 2 in the third year. The increase of chemotherapy cycle can obviously reduce the relapse rate and improve the long-term prognosis of @entity1 . It is worth to further explore.
